Global InformationAstraZeneca information
 | |
 Corporate HQ in Cambridge, England | |
| Company type | Public |
|---|---|
Traded as |
|
| ISIN | GB0009895292 |
| Industry |
|
| Predecessors |
|
| Founded | 6 April 1999 |
| Headquarters | Cambridge Biomedical Campus, Cambridge , England, UK |
Area served | Global |
Key people |
|
| Products | Pharmaceutical products |
| Revenue |  US$45.811 billion (2023)[1] |
Operating income | US$8.193 billion (2023)[1] |
Net income | US$5.961 billion (2023)[1] |
| Total assets | US$101.119 billion (2023)[1] |
| Total equity | US$39.166 billion (2023)[1] |
Number of employees | 89,900 (2023)[1] |
| Subsidiaries |
|
| Website | astrazeneca |
AstraZeneca plc (/ˌæstrəˈzɛnəkə/) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company[2][3][4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.[5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.[6]
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group[7][8] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden and Gaithersburg in Maryland, U.S.[9]
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Its British counterpart, Zeneca PLC was formed in 1993 when ICI divested its pharmaceuticals businesses; Astra AB and Zeneca PLC merged six years later, with the chosen headquarters in the United Kingdom.[10]
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.[11]
- ^ a b c d e f "Annual Results 2023" (PDF). AstraZeneca. Retrieved 21 February 2024.
- ^ "AstraZeneca > GC Powerlist: Sweden Teams 2019". www.legal500.com. Retrieved 30 December 2020.
- ^ Hollingsworth, Julia; Renton, Adam; Macaya, Melissa; Hayes, Mike (30 December 2020). "UK "will be able to get out of this by the spring", minister says after regulator approves AstraZeneca vaccine". CNN. Retrieved 30 December 2020.
- ^ biopharma-reporter.com. "AstraZeneca's COVID-19 vaccine gets the green light in the UK". biopharma-reporter.com. Retrieved 30 December 2020.
- ^ "Registered office and corporate headquarters". AstraZeneca. Retrieved 27 February 2020.
- ^ "A history of AstraZeneca". pharmaphorum.com. 18 September 2020. Retrieved 31 March 2021.
- ^ "Global 500 – Pharmaceuticals". Fortune. 20 July 2009. Archived from the original on 23 August 2010. Retrieved 19 August 2010.
- ^ "Key facts". AstraZeneca. Archived from the original on 8 September 2010. Retrieved 1 September 2010.
- ^ Cite error: The named reference
Fierce2013reorgwas invoked but never defined (see the help page). - ^ "A history of AstraZeneca". pharmaphorum. Retrieved 29 October 2023.
- ^ "Largest pharma companies by market cap". companiesmarketcap.com. Retrieved 29 October 2023.